Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates
- PMID: 15148558
- DOI: 10.1007/s00223-004-0103-3
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates
Abstract
The aim of this study was to evaluate the efficacy and safety of risedronate and pamidronate in 30 patients (mean age = 57.86 +/- 8.90 years) with severe Paget's disease of bone (PDB), showing acquired resistance to intravenous (IV) clodronate treatment. Fifteen patients were treated with oral risedronate (30 mg/day for 8 weeks). Treatment was repeated in patients without evidence of PDB remission [total alkaline phosphatase (tALP) serum levels in the normal range] at day 120. Fifteen patients were treated with IV pamidronate (30 mg/day for 3 days). Pamidronate treatment (60 mg/day for 3 days) was repeated in patients without evidence of PDB remission at day 120. At day 60, a significant decrease in tALP serum levels was obtained in all pagetic patients. At day 360, 13 (86.6%) patients treated with risedronate achieved PDB remission, 9 patients during the initial treatment and 4 after retreatment. Two patients showed a significant decrease in tALP serum levels without clinical remission after two risedronate treatments. At the same time, 12 (80%) patients treated with pamidronate achieved PDB remission, 6 patients during the first treatment and 6 after retreatment. Three patients showed a significant decrease in tALP serum levels but no clinical remission after two pamidronate courses. Two of these patients showed a relapse during the study. The incidence of minor side effects and transient hyperparathyroidism related to bisphosphonate treatment was significantly lower after risedronate therapy. In patients with resistant PDB, oral risedronate therapy has comparable efficacy to IV pamidronate with a lower incidence of treatment-related side effects.
Similar articles
-
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.Curr Med Res Opin. 2008 Mar;24(3):695-705. doi: 10.1185/030079908X260899. Epub 2008 Jan 25. Curr Med Res Opin. 2008. PMID: 18226324 Review.
-
Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.J Bone Miner Res. 1998 Jun;13(6):1032-8. doi: 10.1359/jbmr.1998.13.6.1032. J Bone Miner Res. 1998. PMID: 9626635 Clinical Trial.
-
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.Bone. 2004 Apr;34(4):747-54. doi: 10.1016/j.bone.2003.12.011. Bone. 2004. PMID: 15050907 Clinical Trial.
-
Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.J Bone Miner Res. 2007 Oct;22(10):1510-7. doi: 10.1359/jbmr.070704. J Bone Miner Res. 2007. PMID: 17605632 Clinical Trial.
-
Medical management of Paget's disease of bone: indications for treatment and review of current therapies.J Bone Miner Res. 2006 Dec;21 Suppl 2:P94-8. doi: 10.1359/jbmr.06s218. J Bone Miner Res. 2006. PMID: 17229018 Review.
Cited by
-
Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.Ther Adv Musculoskelet Dis. 2009 Apr;1(2):107-25. doi: 10.1177/1759720X09351779. Ther Adv Musculoskelet Dis. 2009. PMID: 22870432 Free PMC article.
-
Genetic Determinants of Paget's Disease of Bone.Curr Osteoporos Rep. 2021 Jun;19(3):327-337. doi: 10.1007/s11914-021-00676-w. Epub 2021 May 14. Curr Osteoporos Rep. 2021. PMID: 33988819 Free PMC article. Review.
-
Diagnosis and treatment of Paget's disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS).J Endocrinol Invest. 2024 Jun;47(6):1335-1360. doi: 10.1007/s40618-024-02318-1. Epub 2024 Mar 15. J Endocrinol Invest. 2024. PMID: 38488978 Free PMC article. Review.
-
Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.J Bone Miner Metab. 2010 Jul;28(4):468-76. doi: 10.1007/s00774-009-0152-9. Epub 2010 Feb 24. J Bone Miner Metab. 2010. PMID: 20179977 Clinical Trial.
-
Influence Of Angiogenic Mediators And Bone Remodelling In Paget´s Disease Of Bone.Int J Med Sci. 2018 Jul 30;15(11):1210-1216. doi: 10.7150/ijms.26580. eCollection 2018. Int J Med Sci. 2018. PMID: 30123059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical